IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications-Reference-Cited by-同舟云学术

IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications

Published:2023-08 Issue:8 Volume:34 Page:693-702
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Burotto M.,Zvirbule Z.,Mochalova A.,Runglodvatana Y.,Herraez-Baranda L.,Liu S.N.,Chan P.,Shearer-Kang E.,Liu X.,Tosti N.,Zanghi J.A.,Leutgeb B.,Felip E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference45 articles.

1. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer;Schmid;N Engl J Med,2018

2. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer;Horn;N Engl J Med,2018

3. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial;Balar;Lancet,2017

4. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020

5. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial;Gutzmer;Lancet,2020

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study;Journal of Pharmaceutical Health Care and Sciences;2024-08-27

2. An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab;Targeted Oncology;2024-07-31

3. Deciphering Drug Resistance: Investigating the Emerging Role of Hyaluronan Metabolism and Signaling and Tumor Extracellular Matrix in Cancer Chemotherapy;International Journal of Molecular Sciences;2024-07-11

4. The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations;Trends in Cancer;2024-07

5. Pros and cons of subcutaneous (SC) versus intravenous (IV) administration of immune checkpoint inhibitors in non-small cell lung cancer;Translational Lung Cancer Research;2024-06